Search
A European Reference Network for Rare Hematological Diseases
You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.
Read moreThe importance of education and collaboration for the treatment of patients
This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here
Read moreMeeting Report: European School of Haematology International Conference of Haematological Disorders in the Elderly
The meeting started by reviewing demographic aspects, physiological changes encountered in the elderly, as well as the definition of older and elderly people, frailty and comorbidity.
Read moreEHA - Access to Medicine
By reporting the unavailability of hematology medicine you are strengthening our efforts to improve patients' access to medicine across Europe. REPORT NOW
Read moreEHA-SWG Scientific Meeting: Focus on Thrombocytopenia & platelet function disorders
Click here for the full report of the EHA-SWG Scientific Meeting
Read moreSanquin Blood Supply will culture erythrocytes for transfusion purposes
ABO-Rh-D matched transfusions result in alloimmunisation in 3-5% of recipients. Once allo-immunized, it may become very difficult to find appropriate donor erythrocytes, especially when multiple antibodies or rare combinations of antibodies are present.
Read moreTargeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read moreDaratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.
Read moreMini-hormone fights iron
Iron overload commonly leads to organ damage and even death. Currently available treatments for iron overload are burdensome or cause side effects.
Read moreTARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS
Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- »